镭-223预处理对镥-177-PSMA放射性配体治疗转移性去势抵抗性前列腺癌患者肿瘤控制结局的影响
基于FRAMCAP数据库分析329例接受镥-177-PSMA放射性配体治疗的转移性去势抵抗性前列腺癌患者,其中19%曾接受镭-223预处理。结论认为镭-223序贯治疗不影响镥-177-PSMA的PFS或OS结局。
要点
- 多因素校正后两组PFS和OS仍无差异,提示镭-223序贯不影响镥-177-PSMA疗效。
核心结论
- 镭-223预处理不影响镥-177-PSMA放射性配体治疗mCRPC患者的PFS或OS结局。
- 该真实世界队列提示两种放射性药物均可在mCRPC治疗流程中序贯使用。
研究设计与样本
- 基于Frankfurt Metastatic Cancer database of the Prostate(FRAMCAP)数据库的分析。
- 纳入329例接受镥-177-PSMA放射性配体治疗的mCRPC患者,治疗线次为第1至第7线。
- 比较镭-223预处理组(19%)与镭-223未预处理对照组(81%)的PFS和OS。
主要发现
- 镭-223预处理组中位mCRPC全身治疗给药次数显著高于未预处理组(4次 vs 3次,p<0.01)。
- 两组其余基线特征及镥-177-PSMA治疗下的PSA反应相似。
- 多因素校正后两组PFS和OS结局仍无差异。
临床怎么用
- 作者认为,基于该真实世界队列,镭-223与镥-177-PSMA两种放射性药物均可在mCRPC治疗流程中序贯使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radium- 223 and Lutetium- 177 prostate-specific membrane antigen radioligand therapy (Lu- 177-PSMA) are approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Data on cancer-control outcomes of sequential therapy of Lu- 177-PSMA after radium- 223 are rare. METHODS: Using the Frankfurt Metastatic Cancer database of the Prostate (FRAMCAP) database, we analyzed progression-free (PFS) and overall (OS) survival of patients after radium- 223 pretreatment vs. radium- 223-naïve controls undergoing Lu- 177-PSMA radioligand within 1 st- 7 th line mCRPC treatment. RESULTS: Of 329 Lu- 177-PSMA mCRPC patients 19% were radium- 223 pretreated, while 81% radium- 223-naïve. The median number of administered mCRPC systemic treatment administrations were significantly higher for radium- 223 pretreated patients (4 vs. 3, p < 0.01). No difference in further baseline or cancer characteristics were observed, similar to PSA response under Lu- 177-PSMA treatment. In PFS analyses, no significant difference between radium- 223 pretreated vs. radium- 223-naïve Lu- 177-PSMA mCRPC patients were observed, with median PFS of 16 vs. 12 months (hazard ratio [HR]: 0.73, confidence interval [CI]: 0.52-1.02, p = 0.063). In OS analysis, also no significant differences were observed with median OS of 18 vs. 15 months for radium- 223 pretreated vs. radium- 223-naïve Lu- 177-PSMA mCRPC patients (HR: 0.99, CI: 0.71-1.37, p > 0.9). Finally, after additional multivariable adjustment, no differences in PFS and OS outcomes between both groups were observed. CONCLUSION: Sequential treatment with radium- 223 prior to Lu- 177-PSMA does not affect PFS or OS outcomes in mCRPC patients. Therefore, this real-world cohort suggests that both radiopharmaceuticals can be administered within mCRPC treatment algorithm.
引用
- Wenzel M, Theissen L, Groener D, et al. Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients. Eur J Nucl Med Mol Imaging. 2025. PMID: 40192790. doi:10.1007/s00259-025-07256-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。